News | February 24, 2026
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
The order will cover the manufacturing of bulk vaccine in 2026
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
Subscribe To Our Newsletter & Stay Updated
